

# Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Brad Sorensen

312-265-9574

bsorensen@zacks.com

scr.zacks.com

10 S. Riverside Plaza, Chicago, IL 60606

## Ensysce Biosciences

(ENSC-NASDAQ)

### ENSC: Publishes Confirmation of Positive Results and Bolsters Cash

ENSC is a clinical stage pharmaceutical company dedicated to bringing a novel opioid to the market that resists the addictive properties that have plagued society.

### OUTLOOK

Ensyesce Biosciences is committed to finding a solution to the opioid crisis plaguing the US and other developed countries around the world. Through its proprietary TAAP technology Ensyesce is in the process of receiving approval for an abuse-resistant yet still pain-relieving opioid.

The company announced that has published a manuscript in a peer-reviewed journal highlighting the successes of PF614. Management also announced that it had bolstered cash reserves to fund critical upcoming trials.

Current Price (02/15/24) \$0.89  
Valuation \$17.50

### SUMMARY DATA

52-Week High \$8.58  
52-Week Low \$0.80  
One-Year Return (%) -88.04  
Beta 0.88  
Average Daily Volume (sh) 375,326

Shares Outstanding (mil) 3  
Market Capitalization (\$mil) \$3  
Short Interest Ratio (days) N/A  
Institutional Ownership (%) 31  
Insider Ownership (%) 53

Annual Cash Dividend \$0.00  
Dividend Yield (%) 0.00

5-Yr. Historical Growth Rates  
Sales (%) N/A  
Earnings Per Share (%) N/A  
Dividend (%) N/A

P/E using TTM EPS N/A  
P/E using 2023 Estimate N/A  
P/E using 2024 Estimate N/A

Zacks Rank N/A

Risk Level High  
Type of Stock Small-Blend  
Industry Med-Biomed/Gene

### ZACKS ESTIMATES

#### Revenue

(in millions of \$)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2021	N/A	N/A	1.2A	0.4E	1.7A
2022	0.6A	0.2A	0.3A	1.4A	2.5A
2023	0.8A	0.5A	0.4A	0.3E	2.0E
2024	0.2E	0.3E	0.3E	0.3E	1.1E

#### Earnings per share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2021	N/A	-0.39A	-0.71A	0.45A	-1.48A
2022	-0.06A	-0.24A	-5.13A	-2.55A	11.62A*
2023	-2.08A	-0.98A	-0.87A	-0.93E	-4.86E
2024	-0.85E	-0.86E	-0.89E	-0.93E	-3.53E

\*quarters don't add to yearly total in 2022 due to reverse stock split and share issuance.

---

## Update

Ensysce Biosciences (ENSC) announced that it has published a manuscript in the peer-reviewed medical journal Clinical and Translational Science. The manuscript highlighted its PF614 drug, and the testing done that compared it to OxyContin. The tests showed that PF614, which is abuse resistant as we've described in detail in previous reports, has comparable pain relief properties as OxyContin, while also having the additional benefit of having a longer half-life.

As a reminder, these tests have shown that PF614 can provide the much-needed pain relief that is currently available through the highly abused oxycodone, while having abuse resistant properties and lasting longer. We are again reiterating our belief that the treatments being developed by Ensysce will be game changers in the pain relief market and again suggest that investors take a strong look at ENSC.

In an effort to solidify the company's cash position heading into the crucial Phase 3 trial of PF614, the company announced that it had entered into an agreement for the immediate exercise of certain outstanding warrants that will result in the company bolstering its cash balance by approximately \$4.7 million, minus fees associated with the action. In consideration for the immediate exercise of warrants, Ensysce is issuing new unregistered warrants to purchase up to 7.2 million shares of common stock at an exercise price of \$1.06.


We applaud this move as it gives the company the cash it needs to both solidify its balance sheet and fund the upcoming Phase 3 trial.

Ensysce Biosciences continues to be one of the companies that we cover that we believe most of America would hope is successful and one we are becoming more convinced will achieve its goals. The opioid crisis remains a plague on the American public and is destroying families and entire communities. The National Institute on Drug Abuse reported more than 107,000 overdose deaths in 2022—and that doesn't count the millions of family members and friends impacted by those deaths. Ensysce has extremely promising technology in the form of PF614 and PF614-MPAR that are abuse resistant, while still providing the much-needed pain relief that many Americans need with a longer lasting dose than its bioequivalent OxyContin.

We've talked about PF614, but the company is also developing PF614-MPAR, which has been shown in testing to have the potential to provide much needed pain relief to patients but provides protections against taking too many pills, which often leads to debilitating addiction. The technology involved causes the drug to become inactive when dosing requirements are exceeded—greatly diminishing the "incentive" patients may have to take more than the prescribed dose.

Our confidence in the ultimate approval of these important drugs continues to grow as the company recently added the BTB designation for PF614-MPAR to the Fast Track designation already received for PF614 and continues to obtain the financing needed, as noted above, to continue the testing process. Events such as the BTB designation can happen quickly and without notice, illustrating why we have been suggesting investors look into ENSC before these events occur. Major tests are coming in the not-to-distant future, and we believe, based on the data we've seen from earlier tests, that the results will be quite positive and propel the stock higher.

## HISTORICAL STOCK PRICE



## DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

### ANALYST DISCLOSURES

I, Brad Sorensen, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

### INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

### POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.

SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover.

SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

### ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

### CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.